Medication Monitor

Generic Name (Trade Name—Company)
December 20, 2018


(Herzuma—Celltrion )
Biosimilar to trastuzumab approved for patients with HER2-overexpressing breast cancer

FDA approved trastuzumab-pkrb, a HER2/neu receptor antagonist, as a biosimilar to trastuzumab (Herceptin) for patients with HER2-overexpressing breast cancer.  

Common expected adverse effects include headache, diarrhea, nausea, chills, fever, infection, congestive heart failure, insomnia, cough, and rash. Serious expected adverse include worsening of chemotherapy-induced neutropenia.  

Like trastuzumab, the labeling for trastuzumab-pkrb contains a boxed warning to alert health professionals and patients about increased risks of cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity.